The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia

BMC Pulmonary Medicine

Volumn 5, Issue , 2005, Pages

  Mortensen, Eric M ^a,b   Restrepo, Marcos I ^a,c   Anzueto, Antonio ^c   Pugh, Jacqueline ^a,b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TEACHING HOSPITAL; THORAX RADIOGRAPHY; COMMUNICABLE DISEASE; MIDDLE AGED; PNEUMONIA; RISK FACTOR; STATISTICS;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALS, TEACHING; HUMANS; INPATIENTS; MALE; MIDDLE AGED; OUTPATIENTS; PNEUMONIA; RETROSPECTIVE STUDIES; RISK ADJUSTMENT; RISK FACTORS;

EID: 26844485470     PISSN: 14712466     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-5-12     Document Type: Article

References (20)

1. Hoyert DL, Arias E, Smith BL: Deaths: Final Data for 1999. Natl Vital Statistics Report 2001, 49(8):1-113.
2. Gilbert K, Fine MJ: Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Seminars in Respiratory Infections 1994, 9(3):140-152.
3. Nakayama K, Sekizawa K, Sasaki H: ACE inhibitor and swallowing reflex. Chest 1998, 113(5):1425.
4. Okaishi K, Morimoto S, Fukuo K, Niinobu T, Hata S, Onishi T, Ogihara T: Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly inpatients. Am J Hypertens 1999, 12(8 Pt 1):778-783.
5. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J: Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004, 169(9):1041-1045.
6. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Froland SS, Fowler M: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. Journal of the American College of Cardiology 1999, 34(7):2061-2067.
7. Alkharfy KM, Kellum JA, Matzke GR: Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock 2000, 13(5):346-360.
8. Skerrett SJ, Park DR: Anti-inflammatory treatment of acute and chronic pneumonia. Seminars in Respiratory Infections 2001, 16(1):76-84.
9. Moussa K, Michie HJ, Cree IA, McCafferty AC, Winter JH, Dhillon DP, Stephens S, Brown RA: Phagocyte function and cytokine production in community acquired pneumonia. Thorax 1994, 49(2):107-111.
10. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C: Patterns of cytokine expression in community-acquired pneumonia. Chest 1995, 107(5):1342-1349.
11. Bauer TT, Monton C, Torres A, Cabello H, Fillela X, Maldonado A, Nicolas JM, Zavala E: Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 2000, 55(1):46-52.
12. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997, 278(23):2080-2084.
13. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163(7):1730-1754.
14. Bartlett JG, Dowell SF, Mandell LA, File Jr TM, Musher DM, Fine MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31(2):347-382.
15. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250.
16. Mortensen EM, Kapoor WN, Chang CC, Fine MJ: Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003, 37(12):1617-1624.
17. Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ: Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002, 162(9):1059-1064.
18. Stone RA, Obrosky DS, Singer DE, Kapoor WN, Fine MJ: Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators. Med Care 1995, 33(4 Suppl):AS56-66.
19. Mortensen EM, Restrepo M, Anzueto A, Pugh J: Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004, 117(10):726-731.
20. Klungel OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BH, Leufkens HG, de Boer A: Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004, 57(12):1223-1231.